作者
Huilei Zhao, Yang Liu, Menglu Liu, Yi Xu, Qin Ling, Weichun Lin, Jing Zhang, Zhiwei Yan, Jianyong Ma, Weiguang Li, Yujie Zhao, Peng Yu, Xiao Liu, Jingfeng Wang
发表日期
2023/9
来源
Drugs
卷号
83
期号
14
页码范围
1293-1307
出版商
Springer International Publishing
简介
Background
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). However, there remains uncertainty about the efficiency of GLP-1 RAs in patients with heart failure (HF).
Methods
Randomized placebo-controlled trials (RCTs) that reported the effect of GLP-1 RAs on prognosis in patients with HF were identified by searching databases. The primary outcome was defined as MACE. Trail Sequential Analysis (TSA) was used to evaluate the reality and authenticity.
Results
Nine RCTs involving 8920 patients with HF were included. GLP-1 RAs significantly reduced the risk of MACE compared with placebo (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.77–0.98) in HF coexisting with T2DM. The benefit was not observed in all-cause death (HR 0.99, 95% CI 0.84–1.15), hospitalization for heart failure (HR …
学术搜索中的文章
H Zhao, Y Liu, M Liu, Y Xu, Q Ling, W Lin, J Zhang… - Drugs, 2023